FDA approves OptiNose's Xhance for nasal polyposis

OptiNose Inc. (NASDAQ:OPTN) expects to launch Xhance (OPN-375) in 2Q18 following the intranasal fluticasone propionate’s approval by FDA in September to treat nasal polyposis in adults. The corticoste...